Validive may be effective for prevention of severe oral mucositis
the ONA take:
Onexo S.A., has announced positive preliminary results from its phase 2 clinical study of its investigational drug Validive for the prevention and treatment of severe oral mucositis in patients with head and neck cancer receiving postoperative radiochemotherapy. Validive is a buccal tablet of clonidine that uses the mucoadhesive technology Lauriad.
For the double-blind, placebo-controlled study, 183 patients were randomly assigned to receive Validive 50μg, Validive 100μg, or placebo. Results showed an overall incidence of severe oral mucositis of 45%, 16% less than those who received placebo. Occurrence of severe oral mucositis was also found to be delayed in the Validive groups versus placebo.
Both Validive groups experienced improvement in conditions associated with severe oral mucositis and radiotherapy, such as dysphagia, nausea, and vomiting. In addition, there was no significant difference in effectiveness between the 50μg and 100μg groups. Both groups of Validive were well tolerated and demonstrated a good safety profile.
Furthermore, patients were found to be very compliant; over 80% of patients applied Validive or placebo to the gum every day during treatment. Onexo S.A. plans to begin a phase 3 clinical trial in 2015 to investigate Validive further.
Positive results of drug Validive for treatment of severe oral mucositis in patients with head and neck cancer.
Onxeo S.A., an innovative biopharmaceutical company specializing in the development of orphan oncology drugs, has announced positive preliminary top-line results from its Phase II clinical trial of Validive® (mucoadhesive buccal tablet MBT clonidine Lauriad®) for prevention of severe oral mucositis (OM). Oral mucositis is a radio/chemotherapy related condition occurring very frequently in patients undergoing head and neck cancer treatment.
Based on the well-established WHO scale, OM is considered as "non severe" for grades 0 to 2, based on level of pain and burden for the patients. >From grade 3 to 4, OM is rated severe, based on symptoms such as pain and mouth dryness which prevents patients from drinking and eating and induces increased hospitalization and treatment breaks. With no curative or preventive treatment currently, OM represents a serious unmet medical need for the patients.
- Acupuncture an Effective Alternative Treatment for Cancer-Related Fatigue
- Compound in Teas, Peas, Soybeans May Increases Prostate Cancer Risk
- Response to Anemia Treatment Differs in Lymphoma, Multiple Myeloma
- Fertility Preservation in Male Adolescents and Young Adults With Cancer
- Social, Psychiatric Variables Reduce Cognitive Functioning, QoL in HNC
- HPV and Cancer (Fact Sheet)
- Pain Control More Easily Achieved With Nurse-Led Education in Bone Metastases
- Using Nutrition-Based Strategies to Manage Adverse Effects of Cancer
- Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer
- A Case of Immunotherapy-Induced Myocarditis Concomitant to MG in Lung Cancer
- Online Learning Modules Improve Exercise Counseling, But Not Participation
- ASCO Issues Statement Addressing Alcohol and Cancer
- Duloxetine May Improve AI-Associated Joint Pain in Early Stage Breast Cancer
- Axillary Lymph Node Dissection Predictive for Lymphedema in Breast Cancer
- Drug Combination Does Not Extend Glioblastoma Survival
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|